Ahn-Gook Pharmaceutical Co. Ltd (001540) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Ahn-Gook Pharmaceutical Co. Ltd (001540) has a cash flow conversion efficiency ratio of 0.086x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩14.44 Billion ≈ $9.79 Million USD) by net assets (₩167.29 Billion ≈ $113.37 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of Ahn-Gook Pharmaceutical Co. Ltd for the company's overall valuation and market capitalisation.
Ahn-Gook Pharmaceutical Co. Ltd - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Ahn-Gook Pharmaceutical Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Ahn-Gook Pharmaceutical Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ahn-Gook Pharmaceutical Co. Ltd ranked by their cash flow conversion efficiency. Explore Ahn-Gook Pharmaceutical Co. Ltd cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Single Well Industrial
TWO:3490
|
-0.002x |
|
Abionyx Pharma SA
PA:ABNX
|
-0.314x |
|
Saunders International Ltd
AU:SND
|
0.229x |
|
Welltend Technology Corp
TW:3021
|
0.056x |
|
Associated Capital Group Inc
NYSE:AC
|
-0.045x |
|
Mediaco Holding Inc
NASDAQ:MDIA
|
-0.057x |
|
NICE Total Cash Management Co. Ltd
KQ:063570
|
0.149x |
|
Blink Charging Co
NASDAQ:BLNK
|
0.011x |
Annual Cash Flow Conversion Efficiency for Ahn-Gook Pharmaceutical Co. Ltd (2012–2024)
The table below shows the annual cash flow conversion efficiency of Ahn-Gook Pharmaceutical Co. Ltd from 2012 to 2024. View 001540 stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩165.68 Billion ≈ $112.28 Million |
₩4.91 Billion ≈ $3.33 Million |
0.030x | +438.78% |
| 2023-12-31 | ₩151.67 Billion ≈ $102.78 Million |
₩-1.33 Billion ≈ $-899.86K |
-0.009x | -175.78% |
| 2022-12-31 | ₩154.80 Billion ≈ $104.90 Million |
₩1.79 Billion ≈ $1.21 Million |
0.012x | +14.00% |
| 2021-12-31 | ₩145.26 Billion ≈ $98.44 Million |
₩1.47 Billion ≈ $997.66K |
0.010x | -86.95% |
| 2020-12-31 | ₩144.10 Billion ≈ $97.65 Million |
₩11.19 Billion ≈ $7.58 Million |
0.078x | -47.86% |
| 2019-12-31 | ₩148.25 Billion ≈ $100.46 Million |
₩22.08 Billion ≈ $14.96 Million |
0.149x | +1919.68% |
| 2018-12-31 | ₩146.77 Billion ≈ $99.46 Million |
₩-1.20 Billion ≈ $-814.03K |
-0.008x | -106.42% |
| 2017-12-31 | ₩136.96 Billion ≈ $92.81 Million |
₩17.46 Billion ≈ $11.84 Million |
0.128x | +32.23% |
| 2016-12-31 | ₩130.89 Billion ≈ $88.70 Million |
₩12.62 Billion ≈ $8.55 Million |
0.096x | -33.85% |
| 2015-12-31 | ₩131.06 Billion ≈ $88.82 Million |
₩19.11 Billion ≈ $12.95 Million |
0.146x | +1287.76% |
| 2014-12-31 | ₩122.46 Billion ≈ $82.99 Million |
₩1.29 Billion ≈ $871.80K |
0.011x | -63.54% |
| 2013-12-31 | ₩126.42 Billion ≈ $85.67 Million |
₩3.64 Billion ≈ $2.47 Million |
0.029x | -71.39% |
| 2012-12-31 | ₩114.36 Billion ≈ $77.50 Million |
₩11.51 Billion ≈ $7.80 Million |
0.101x | -- |
About Ahn-Gook Pharmaceutical Co. Ltd
Ahn-Gook Pharmaceutical Co., Ltd. manufactures and sells pharmaceutical products. The company's pharmaceutical products include Cinatura and Revo Tension. The company was founded in 1959 and is headquartered in Seoul, South Korea.